404
+1-313-307-4176
Human Microbiome Market Report
The Global Human Microbiome Market is segmented By Product (Probiotics, Prebiotics, Medical Foods, Supplements, Diagnostic Devices, Others), By Application (Therapeutics, Diagnostics), By Disease (Obesity, Diabetes, Autoimmune Disorder, Metabolic & Gastrointestinal Disorders, Cancer, Others), and Region....
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Global Human Microbiome Market is projected to grow from USD 520.5 million in 2020 to USD 1,822.3 million by 2026 at a CAGR of over 23.2% during the forecast period.
Figure: Global Human Microbiome Market Size, 2020-2026 (USD Million)
Want to know segmentation details? Register Here
Human tissues are covered with millions of microorganisms such as viruses, bacteria, and fungi, which are known as human microbiota. All the genes present inside these organisms are called as microbiome. Human microbiomes play a vital role in advanced healthcare, as it enables to allow easy digestion of food, production of vitamins such as Vitamin K, B, and B12 which is important for blood coagulation. These microbiomes improves human nutrition and immunity.
Key players operating in the global human microbiome market are
Growing prevalence of C. Difficile infection (CDI) is a key factor driving the demand for human microbiome.
Based on application, the global human microbiome market has been bifurcated into therapeutics and diagnostics.
By region, the North America market garnered the highest market share in 2020 and is projected to grow at a healthy CAGR during the assessment period.
The COVID-19 pandemic has adversely affected the human microbiome industry including their preclinical studies and clinical trials of microbiome-based therapeutics and diagnostics products. Furthermore, the COVID-19 pandemic has focused the need for manufacturing companies and R&D organizations to collaborate with the government to innovate therapeutics and diagnostics, to meet future health crises. Several universities and major market players are focusing on developing interventions for coronavirus.
Want to know the full scope of the report? Register Here
The following is a list of the customers that the Human Microbiome market aims to convert the most:
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The human microbiome market size is expected to reach USD 1,822.3 million in the foreseeable future.
The human microbiome market is expected to witness an impressive growth of 23.2% CAGR in the foreseeable future.
ENTEROME (France), Yakult (Japan), DuPont de Nemours, Inc. (The U.S), Metabiomics Corporation (The U.S), ViThera Pharmaceuticals, Inc. (The U.S), Second Genome Inc. (The U.S), MICROBIOME THERAPEUTICS LLC (The U.S), Vedanta Biosciences, Inc. (The U.S), Osel, Inc. (The U.S), Merck Sharp & Dohme Corp (The U.S), Seres Therapeutics (The U.S) and Synthetic Biologics, Inc. (The U.S) are among the key players in the human microbiome market.
North America garnered the largest share of human microbiome market in 2020.
The therapeutics segment held the largest share of human microbiome market in 2020.
Growing prevalence of C. Difficile infection, the introduction of probiotics, rising collaborations between public-private organizations are the factors driving the growth of human microbiome market.
Human microbiome companies, Human microbiome vendors, R&D organizations, Hospitals, Government organizations are the target audience in the human microbiome market.
WE ACCEPT
